Posted inBiotechnology Alphabet spinoff SandboxAQ raises $300M fund for ‘next wave of AI’ December 18, 2024 Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas including drug…
Posted inBiotechnology Lawsuit accuses Applied Therapeutics of misleading investors before FDA rejection December 18, 2024 After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with…
Posted inBiotechnology Editor’s Corner: Fierce Biotech’s 10 most-read stories of 2024 December 18, 2024 For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting.…
Posted inBiotechnology Ring Therapeutics lays off just under half of staff in 2nd wave of cuts this year, CEO set to step down December 18, 2024 Ring Therapeutics, a Flagship Pioneering-backed biotech developing new viral vectors for gene therapy delivery, has cut its staff by just…
Posted inBiotechnology Novartis, BioAge take on age-related diseases in $550M pact December 18, 2024 Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and includes the possibility…
Posted inBiotechnology Fibrosis-focused Tvardi to go public via merger with cash-strapped Cara December 18, 2024 Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and the biotech has now found a new…
Posted inBiotechnology Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh’s preclinical drug December 18, 2024 Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for…
Posted inBiotechnology Aurion’s regenerative eye disease med improves vision in phase 1/2 trial December 18, 2024 The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has improved…
Posted inBiotechnology Cognition’s phase 2 SHIMMER results finally allow dementia drug to shine December 18, 2024 The failure of Cognition Therapeutics’ Alzheimer’s disease candidate CT1812 in the SHINE trial earlier this year may have rubbed off…
Posted inBiotechnology Novo Nordisk taps Photys for $186M cardiometabolic collab December 17, 2024 With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a concerted…